Aktuellt
SENASTE
We estimate Q3 Catalyst sales of SEK 15.6m, corresponding to y/y growth of 138%, driven by continued uptake and increased use, but the main driver being new users. We account for a SEK 15m one-off cost related to the ongoing discontinuation of Cranial PSI but expect a limited impact on sales due to the announcement coming late in Q3. The Q4 Cranial sales decrease is tough to assess as lead times and timing can affect it. We reiterate our mid-point of SEK 9.
LÄS MER
